Empowered by CRISPR- and shRNA-based functional genomics, a plethora of novel factors required for KRAS-mutant cancer cells have been identified [12–16, 26], although the long-sought-after universal synthetic lethal targets for KRAS-driven pan-cancers are still at large. Here, KRAS is linked to cancer.